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Moyamoya disease is a cerebrovascular disease with progressive occlusion
starting from both internal carotid arteries (ICAs) and extending to their branches,
with concurrent formation of a new vascular network at the base of the brain. The
typical clinical features are cerebral infarction, recurrent transient ischemic
attacks, convulsions and migraine-like headaches in pediatric patients. Although
the incidence is relatively high in Japan, it has also been reported in Western
countries.
1
The pathogenesis of Moyamoya disease is unknown, but hyperactivity of the
cervical sympathetic nerves and autoimmune mechanisms observed in thyroto-
xicosis may contribute to stenosis of the cerebral arteries.
2,3 Although a few cases
with concurrence of Graves’ disease and Moyamoya disease have been reported,
2
a question of whether this leads to an “aggressive autoimmune mechanism”
remains to be settled.
2,4 Excess thyroid hormone in patients with Graves’ disease is
harmful to arterial walls as it may alter vascular reactivity,
5,6 and Graves’ disease
is often accompanied by many cardiovascular symptoms.
7
The diagnosis of a definite case of Moyamoya disease requires fulfillment of
the following angiographic criteria: stenosis or occlusion in the terminal portion of
the ICA and in the proximal portions of the anterior cerebral artery (ACA) and the
middle cerebral artery (MCA); an abnormal vascular network in the vicinity of
the arterial occlusion, and indications of bilateral involvement.
8 The idiopathic or
primary form of Moyamoya disease has to be distinguished from the secondary
form, referred to as Moyamoya syndrome. This syndrome can be associated with
certain systemic conditions such as sickle cell disease, chronic basilar meningitis,
neurofibromatosis, X-ray irradiation, homocysteinuria and Down syndrome.
9
We report a case of Moyamoya disease in a young woman with Down syndrome
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INTRODUCTIONand thyrotoxicosis. We also review relevant literature and
discuss the association of Moyamoya disease with Graves’
disease.
A 19-year-old woman who had suffered from Graves’
disease for four years visited our outpatient clinic with
central type right facial palsy. She also had episodic transient
right-side hemiparesis. She had been diagnosed with
Down syndrome when she was born. Four years before,
she had been admitted to our hospital with diarrhea and a
neck mass. Initial thyroid function testing revealed that the
thyroid-stimulating hormone (TSH) level was 0.001
microunits/mL (reference range, 0.2 - 7.6 microunits/mL),
the triiodothyronine (T3) level was 681 ng/dL (reference
range, 80 - 210 ng/dL), and the free thyroxine (free T4) level
was over 6.0 ng/dL (reference range, 0.7 - 1.7 mg/dL).
Thyroid aspiration study was consistent with diffuse hyper-
plasia, and the patient had also been diagnosed with Graves’
disease. After treatment with propylthiouracil, her hypert-
hyroid symptoms were controlled, with her thyroid hormone
levels maintained at the upper range of normal. Three
years after the treatment for hyperthyroidism, she suddenly
developed weakness in the right upper and lower extre-
mities. She had grade 3 power in the upper extremity
flexors and extensors, and grade 4 in the lower extremity.
The biceps and knee jerk reflexes on the right side were
hypereflexic. We tried to check her brain using magnetic
resonance imaging (MRI), but failed because she was
uncooperative and not sedated. The weakness was pro-
longed for one month, and it then resolved gradually. One
year later, the patient developed right hemiparesis again.
There was no sign of sensory involvement or coordination
abnormalities. At this time, we could perform a brain MRI.
The physical examination at the time of admission revealed
bilateral exophthalmos and a goiter. The patient’s blood
pressure was 135/78 mmHg and her heart rate was 91
beats/min. Electrocardiography demonstrated a regular
sinus rhythm, and echocardiographic results were normal.
Thyroid function tests revealed thyrotoxicosis, with a TSH
level of 0.13 microunits/mL, a T3 level of 221.9 ng/dL and
a free T4 level of 2.46 ng/dL. The TSH receptor antibody
value was 40.09 IU/L (reference range, negative < 1.0 IU/L,
positive > 2.0 IU/L). Other laboratory tests, including
blood cell count, prothrombin time and activated partial
thromboplastin time, yielded normal results.
The neurological examination demonstrated right-side
hemiparesis. The patient showed alert mentality, bidirec-
tional nystagmus, slurred speech and decreased motor
power of grade 4 on the right side. MRI of the brain revealed
bilateral stenosis of the sylvian cisternal MCA and intra-
cavernous ICA, prominent especially on the left; there was
a multiple chronic infarction in the left side deep periven-
tricular white matter (Fig. 1). Angiography demonstrated
bilateral occlusion of the ICA around the supraclinoid
segment with some collateral vessels (Moyamoya vessels).
The ACA and MCA were not visible, and there were trans-
dural collaterals from both middle meningeal arteries and
anterior falx artery to both medial frontal regions (Fig. 2).
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Fig. 2. Angiography showing bilateral occlusion of ICA around supraclinoid
segment (�) with some collateral vessels (Moyamoya vessels, ∆). ACA and
MCA are not visible. 
Fig. 1. (A) Magnetic resonance imaging scans showing bilateral stenosis of
MCA and ICA (�). (B) It is prominent on the left side. Multiple chronic infarction
on the left deep periventricular white matter (∆). 
A
BThe patient was diagnosed with Moyamoya disease with
typical stenosis of the ICA and MCA, based on MRI scans
and cerebral angiography. Single photon emission computed
tomographic (SPECT) scans revealed cerebral hypoper-
fusion of the left frontal, left superior parietal, right superior
anterior frontal and anterior cingulate cortices. The patient
underwent cranial revascularization by encephalo-duro-
arterio-synangiosis (EDAS) and encephalo-myo-synan-
giosis (EMS). A left-side EDAS was done first. Because
the size of the right superficial temporal artery was not
appropriate for EDAS, a right EMS (application of a
temporal muscle flap directly to the pial surface) was done
four months later. After surgery, the patient’s symptoms
improved, and the power of the right upper and lower
extremities recovered to grade 5. There has been no recur-
rence for two years since the last operation. Follow-up
angiography was performed six months after surgery and
demonstrated that both cerebral hemispheres were well
perfused by new transdural collateral vessels. 
Excess thyroid hormone in patients with Graves’ disease is
harmful to arterial walls because it may alter vascular
reactivity,
5,6 and Graves’ disease is often accompanied by
many cardiovascular symptoms.
Thyroid hormone directly affects cardiac myocytes and
endothelial and vascular smooth muscle cells.
10 Hyper-
thyroidism increases heart rate, cardiac output, pulse
pressure and blood pressure.
11 The beta index of stiffness
provides a useful diagnostic indicator for detecting asymp-
tomatic common carotid artery atherosclerosis and
correlates with the severity of atherosclerosis. The beta
index of stiffness measured at the common carotid artery
in hyperthyroid patients with Graves’ disease is increased
significantly, which is thought to be due to the increased
stroke volume found in these patients.
11 Shargorodsky et
al.
12 showed that patients with this condition have lower
large artery elasticity than euthyroid control subjects. Hyper-
thyroidism is associated with a hyperdynamic circulation,
reduced vascular stiffness and enhanced endothelial func-
tion.
11 Demonstration of increased nitric oxide production
and relaxation of vascular smooth muscle in various
studies of hyperthyroidism supports these mechanisms.
11
In our patient, the duration of diagnosed thyrotoxicosis
was four years; however, she might already have had sub-
clinical hyperthyroidism, because she showed exophthal-
mos at the first visit. There are insufficient data regarding
arterial function in patients with subclinical hyperthyroi-
dism, and the evidence for vascular abnormalities in such
cases is unconvincing.
11 We speculate that this patient
might have had vascular alterations due to prolonged
subclinical hyperthyroidism.
There have been few reported cases of Graves’ disease
associated with Moyamoya disease or Moyamoya variants,
including our case (Table 1).
2-4,8,13-18 Both clinical observa-
tions and laboratory evidence of a hyperthyroid state are
associated with the onset of cerebral ischemic events, and
most of the patients recover from their neurologic symp-
toms after completion of medical and/or surgical treatment.
According to a study on the stiffness of common carotid
artery in patients with Graves’ disease, there were strong
correlations between all stiffness parameters and plasma
thyroid hormone concentrations in the untreated patients,
and this relationship remained significant after statistical
corrections for age and lipid levels. The stiffness of the
common carotid artery in untreated patients might be
affected by the thyroid hormone level.
7 Some of these
patients fared well with the use of antithyroid drugs and
the treatment for hyperthyroidism coincided with neurolo-
gical improvements. Therefore, Moyamoya disease might
be asymptomatic, and the cerebral hemodynamic changes
attributable to thyrotoxicosis might be the trigger for vas-
cular attacks, either directly or indirectly. It is practical to
consider patients with both multiple arterial stenoses and
Graves’ disease as being at risk for ischemic cerebrovas-
cular events. Sudden surges of thyroid hormone level
should be avoided, particularly when using radioactive
iodine ablation, which may be more prone to cause these
surges.
4 Careful control of thyroid function is essential, and
surgical revascularization might be considered for selected
patients. 
Another possible link between these disorders is athero-
sclerosis. The positive correlation between free T4 levels
and both homocysteine and methylmalonic acid indicates
the possibility of thyrotoxicosis to induce hyperhomocys-
teinemia.
19 As homocysteinemia has been implicated in
patients with atherosclerotic and embolic disorders,
20 this
could be an another key to the pathophysiology of Moya-
moya disease. Graves’ disease is an autoimmune disorder,
and the associated thyrotoxicosis is thought to enhance the
effects of sympathetic nervous activity. Regional sympa-
thetic nervous stimulation may contribute to pathological
changes, involving the carotid arteries. This may be because
the superior cervical ganglion is adjacent not just to the
cervical lymph nodes but also to the thyroid gland.
Arterial stiffness in the common carotid artery is incr-
eased in patients with hyperthyroidism. The significant
increase in stiffness beta in the hyperthyroid state may
reflect the harmful effect of hyperthyroidism on the arterial
wall, which may in turn result from increased stroke
volume.
6 One possible pathomechanism for the aggravation
of cerebrovascular ischemia in the thyrotoxic state might
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Table 1. Summery of Reported Cases of Moyamoya Syndrome in Association with Graves’ Disease 
Age(yr)   CT  /  MRI  Angiographic 
Thyroid 
Study
/ Sex
Race Symptom
finding findings
condition at  Treatment
vascular accident
Thyrotoxicosis
Moyamoya Antithyroid
Kushima et al.
3 21 / F Japanese recurrent hemiparesis Infarction
disease
Thyrotoxic
therapy
speech disturbance
Kushima et al.
3 22 / F Japanese
Thyrotoxicosis
Infarction
Moyamoya 
Thyrotoxic
Antithyroid 
hemiparesis disease therapy
Liu et al.
13 28 / F Chinese
Thyrotoxicosis
Infarction
Moyamoya 
Thyrotoxic Not described
hemiparesis disease
Tendler et al.
2 37 / F Hispanic
Thyrotoxicosis
Infarction
Moyamoya 
Thyrotoxic
Antithyroid
hemiparesis disease therapy
Moyamoya disease 
Not Moyamoya Antithyroid
Tendler et al.
2 38 / F Caucasian was diagnosed 10 years 
discribed disease
Thyrotoxic
therapy
before thyrotoxicosis
Down syndrome
Moyamoya Antithyroid
Leno et al.
14 21 / M Hispanic hemiparesis Infarction
disease
Thyrotoxic
therapy 
thyrotoxicosis
Thyrotoxicosis Antithyroid 
Kim et al.
15 37 / F Korean
cardiomegaly
Infarction
Moyamoya
Thyrotoxic
therapy furosemide,
pulmonary edema disease digoxin,
seizure dexamethasone
Thyrotoxicosis
Intracranial
Antithyroid
Nakamura et al.
8 23 / F Japanese cardiomegaly Infarction
arterial stenoses
Thyrotoxic therapy / STA-MCA
cerebral infaction bypass + EMS
Upper limits of normal  Infarction /  Intracranial  Upper limits Antithyroid
Nakamura et al.
8 54 / F Japanese range of thyroid  cortical  arterial of normal  therapy / STA-MCA
function, hemiparesis atrophy stenoses range bypass + EMS
Thyrotoxicosis
Moyamoya
Thyroid
Golomb et al.
16 10 / F Caucasian hemiparesis Infarction
disease
Thyrotoxic radioablation /
cerebral infaction pial synangiosis
Sasaki et al.
17 27 / F Japanese
Thyrotoxicosis
Infarction
Moyamoya
Thyrotoxic
Antithyroid
hemiparesis disease therapy / EDAS
Thyrotoxicosis
Moyamoya Antithyroid
Sasaki et al.
17 16 / F Japanese transient ischemic  Infarction
disease
Thyrotoxic
therapy / EDAS
attack (TIA)
Sasaki et al.
17 36 / F Japanese
Thyrotoxicosis
Infarction
Moyamoya
Thyrotoxic
Antithyroid therapy / 
aphasia disease STA-MCA bypass
Thyrotoxicosis
Intracranial 
Hsu et al.
4 40 / F Caucasian
rapid progressive 
Infarction arterial Thyrotoxic Not  described
bilateral cerebral 
stenoses
infarction
Tsai et al.
18 26 / M Chinese
Thyrotoxicosis
Infarction
Intracranial 
Thyrotoxic
Antithyroid 
hemiparesis arterial stenoses therapy
Down syndrome
Moyamoya Antithyroid therapy /
Present report 19 / F Korean hemiparesis Infarction
disease
Thyrotoxic
EDAS + EMS
thyrotoxicosisbe a hemodynamic compromise, induced by an excessive
increase in the cerebral metabolism and oxygen demand,
exceeding the compensation of the cerebral blood flow
deficit through collateral supply in patients with Moyamoya
disease.
21 Therefore, Graves’ disease could be associated
with the causal mechanism of Moyamoya disease.
Other disorders associated with Moyamoya syndrome
have well-established autoimmune mechanisms of patho-
genesis or are associated with arteritis that affects the
cerebral arteries. Such diseases include systemic lupus
erythematosus, antiphospholipid syndrome, ulcerative
colitis, tuberculosis, leptospirosis and postradiation arteritis.
Even seemingly nonvasculitic diseases might have an
autoimmune etiologic linkage, as suggested for patients
with Down syndrome, which has long been known to be
associated with Moyamoya syndrome.
4 Our patient was
diagnosed with Graves’ disease and Down syndrome, and
was simultaneously diagnosed with Moyamoya disease.
Here, we report a case of Moyamoya disease in a young
woman with Down syndrome with thyrotoxicosis. We
suggest that strict control of thyroid function in patients
with hyperthyroidism might help prevent the associated
vascular abnormalities. To our knowledge, this is the first
report of Moyamoya disease associated with thyroto-
xicosis in a young person in Korea.
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